VEGFR-2-IN-85
VEGFR-2-IN-85 is a strong VEGFR-2 inhibitor, with an IC50 value of 0.23 μM. VEGFR-2-IN-85 exhibits potent cytotoxic activity against multiple cancer cell lines with minimal toxicity toward normal cells. VEGFR-2-IN-85 also impairs cancer cell migration, likely through modulation of the VEGFR-2/p-Akt pathway. VEGFR-2-IN-85 can induce apoptosis through modulation of Caspase-3, Bax and Bcl-2. VEGFR-2-IN-85 arrests cell cycle at the G2/M phase and has anti-angiogenic activity. VEGFR-2-IN-85 is a targeted radiosensitizer enhancing radiation-induced cytotoxicity. VEGFR-2-IN-85 can be used for research on cancers such as non-small cell lung cancer, breast cancer, and liver cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C25H23FN4O7S2
- 분자량:574.60
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
|
VEGFR-2 0.23 μM (IC50) |
VEGFR-2-IN-85 (compound 9a) (48 h) exhibits IC50s of 5.02 μM, 4.78 μM, 4.13 μM, 95.87 μM and 62.95 μM in A549, MDA-MB-231, HepG-2, WI-38 and MCF10A cell lines, respectively[1].
VEGFR-2-IN-85 (4.13 μM; 48 h) can effectively interfere with cellular migration associated with angiogenic signaling in HepG-2 cells[1].
VEGFR-2-IN-85 (4.13 μM; 24 h) reduces p-Akt expression in HepG-2 cells, confirming inhibition of VEGFR-2-mediated signaling[1].
VEGFR-2-IN-85 (4.13 μM; 48 h) substantially modulates apoptosis-related markers in HepG-2 cells, emphasized by caspase-3 activation, Bax upregulation and Bcl-2 suppression[1].
VEGFR-2-IN-85 (4.13 μM; 24 h) disrupts cell cycle progression at the G2/M checkpoint in HepG-2 cells, preventing completion of mitosis and limiting proliferation[1].
VEGFR-2-IN-85 (48 h) effectively enhances gamma-induced cytotoxicity in malignant cells while exerting much lower impact on normal cells, with IC50s of 2.10 μM in A549 cells, 1.89 μM in MDA-MB-231 cells, 1.75 μM in HepG-2 cells and 68.74 μM in WI-38 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG-2 cells
-
Concentration:4.13 μM
-
Incubation Time:48 h
-
Result:Limited wound closure to 56.30%, compared with 97.04% in control group.
-
Cell Line:HepG-2 cells
-
Concentration:4.13 μM
-
Incubation Time:24 h
-
Result:Decreased p-Akt level compared with control cells, indicating effective suppression of Akt phosphorylation.
-
Cell Line:HepG-2 cells
-
Concentration:4.13 μM
-
Incubation Time:48 h
-
Result:Upregulated the expression of Caspase-3 and Bax.
Suppressed the expression of Bcl-2.
-
Cell Line:HepG-2 cells
-
Concentration:4.13 μM
-
Incubation Time:24 h
-
Result:Increased the proportion of G2/M cells from 1.35% in untreated controls to 9.57%.
Decreased the G0/G1 population from 87.14% to 78.13%.
Slightly elevated the S phase fraction (12.21% vs. 11.84% in control).
Chemical Information
-
분자량 574.60
-
화학식 C25H23FN4O7S2
-
SMILES
COC1=C(C(OC)=C2N=C(N(C(C2=C1)=O)C3=CC=C(C=C3)S(N)(=O)=O)SCC(NC4=CC=CC=C4F)=O)OC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VEGFR-2-IN-85 Related Classifications
HY-182745 Related Classifications
Powered by Bioz